MULTIPLE MYELOMA KNOWLEDGE CENTER

How is Evomela administered?

Evomela™ (melphalan, Spectrum Pharmaceuticals) is given as an injection into a vein (intravenously or IV).

In myeloma patients receiving high-dose chemotherapy in preparation for an autologous stem cell transplant (ASCT), the recommended dose of Evomela is 100 mg/m2/day administered as an intravenous infusion over 30 minutes. It is given for 2 consecutive days prior to ASCT. This dose may be adjusted in in patients who weigh more than 130% of their ideal body weight.

In myeloma patients receiving Evomela as palliative treatment for symptom or pain relief, the recommended dose is 16 mg/m2 administered as a single intravenous infusion over 12 to 20 minutes. Evomela is administered at 2-week intervals for 4 doses. After adequate recovery from toxicity, Evomela can then be administered every 4 weeks. Reduced doses should be considered for patients who have impaired kidney function.

Patients receiving Evomela also receive medication to help prevent nausea and vomiting.